Abstracts tagged "tobacco use and total joint replacement"

Abstract Number: 2503 • 2018 ACR/ARHP Annual Meeting
Impact of Tobacco Smoking on 1-Year Mortality Following Total Hip and Total Knee Arthroplasty Among Rheumatoid Arthritis Patients – a Danish Cohort Study Using Nationwide Health Care Registers
René Cordtz^1,2, Laerke Bech-Illum³, Daniel Prieto-Alhambra⁴, Pil Hoejgaard^3,5, Kristian Zobbe^3,6, Nina Imbæk³ and Lene Dreyer⁷, ¹Center for Rheumatology and Spine Diseases, Gentofte-Rigshospitalet, Hellerup, Denmark, ²The Parker Institute, Bispebjerg and Frederiksberg Hospital, The Capital Region of Denmark, Copenhagen, Denmark, ³Center for Rheumatology and Spine Diseases - Gentofte, Rigshospitalet, Hellerup, Denmark, ⁴Internal Medicine and Primary Care, URFOA-IMIM, Parc de Salut Mar; Idiap Jordi Gol i Gurina-Institut Català de la Salut; Oxford NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, UK, Barcelona, Spain, ⁵The Parker Institute, Bispebjerg and Frederiksberg Hospital, The Capital Region of Denmark, Denmark, ⁶The Parker Institute, Bispebjerg and Frederiksberg Hospital, Capital Region of Denmark, Copenhagen, Denmark, ⁷Departments of Rheumatology and Clinical Medicine, Aalborg University Hospital and Aalborg University, 9000 Aalborg, Denmark
Background/Purpose: Tobacco smoking and rheumatoid arthritis (RA) are independent risk factors for short-term complications following total hip and total knee arthroplasty (THA/TKA). We aimed to…
Abstract Number: 1425 • 2015 ACR/ARHP Annual Meeting
Current Tobacco Use and the Rates of Complications after Total Hip Arthroplasty
Jasvinder A. Singh, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The risk of postoperative complication with tobacco use disorder and complication after total hip arthroplasty (THA) are not known. Our objective was to compare…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].